Roche Diagnostics will use Response Genetics’ PCR analysis platform to assess HER2 gene expression. The accurate measurement of HER2 gene expression can assist with treatment decisions for cancer patients.
It has been shown that women with HER2-positive gene expression have a three times higher risk of recurrence, even if the cancer is caught in the early stages. HER2 gene amplification has been shown to correlate with improved clinical outcome in response to certain cancer drugs and its measurement by RT PCR was recently shown to correlate with analyses by fluorescence in situ hybridization and immunohistochemistry.
